Presentation is loading. Please wait.

Presentation is loading. Please wait.

S L I D E 0 Elderly Patients Undergoing SBRT for Inoperable Early Stage NSCLC Achieve Similar Outcomes to Younger Patients Brandon R. Mancini, Henry S.

Published byJulian Neal Modified over 9 years ago

Similar presentations

Presentation on theme: "S L I D E 0 Elderly Patients Undergoing SBRT for Inoperable Early Stage NSCLC Achieve Similar Outcomes to Younger Patients Brandon R. Mancini, Henry S."— Presentation transcript:

1 S L I D E 0 Elderly Patients Undergoing SBRT for Inoperable Early Stage NSCLC Achieve Similar Outcomes to Younger Patients Brandon R. Mancini, Henry S. Park, Eileen Harder, Charles E. Rutter, Christopher D. Corso, Roy H. Decker, Zain A. Husain Session title: (DPD 01) Lung 1 - Novel Prognostic Factors and SBRT Session date: September 14, 2014 Abstract number: 1520

2 S L I D E 1 Background / Methods Purpose/Objective(s): To address toxicity and survival achieved with SBRT in the elderly compared to younger patients treated at the same institution. Materials/Methods: –Patients diagnosed with T1-3N0M0 NSCLC treated with SBRT between Sep 2007 and Aug 2013. –SBRT was delivered in 3-5 fractions to 40-60 Gy, with a vast majority of patients receiving 54 Gy in 3 fractions. –Patients were divided into two cohorts, age >75 and <75. –We compared overall survival (OS) and local recurrence-free survival (LRFS) between cohorts.

3 S L I D E 2 Results Age p-value < 75 years old (n=126) > 75 years old (n=127) Median Age (years)68.082.6<0.001 Median Follow-up (months)24.9 Gender (%)1.00 Male70 (55.6)70 (55.1) Female56 (44.4)57 (44.9) T-Stage0.88 T195 (75.4)97 (76.4) T226 (20.6)26 (20.5) T35 (4.0)4 (3.1) ECOG Performance Status (%)0.67 036 (28.6)36 (28.3) 156 (44.4)60 (47.2) 227 (21.4)24 (18.9) 37 (5.6)7 (5.5) Histology (%)0.59 Adenocarcinoma42 (33.3)42 (33.1) Squamous Cell Carcinoma23 (18.3)35 (27.6) Unspecified NSCLC11 (8.7)5 (3.9) Unknown50 (40.0)45 (35.4) Mediastinoscopy (%)0.10 Yes44 (34.9)32 (25.2) No82 (65.1)95 (74.8) Median BED (Gy)151.2 0.32

4 S L I D E 3 Results p=0.95 <75 years 126 83 41 15 3 2 0 ≥75 years 127 78 30 22 7 1 0 Number at Risk 2-Year OS <75 years: 60.2% ≥75 years: 48.9% Median OS <75 years: 29.2 mo ≥75 years: 24.0 mo

5 S L I D E 4 Results p=0.97 <75 years 126 77 37 14 3 2 0 ≥75 years 127 76 28 19 6 1 0 Number at Risk 2-Year LPFS <75 years: 88.5% ≥75 years: 86.2%

6 S L I D E 5 Results Age < 75 years old (n=126) > 75 years old (n=127) Acute6.3%4.7% Increased Dyspnea/Pneumonitis 63 Fatigue03 Chest Wall Pain00 Other20 Late4.0%3.9% Increased Dyspnea/Pneumonitis 34 Fatigue00 Chest Wall Pain10 Other11

7 S L I D E 6 Conclusions To our knowledge, this is the largest single institution study to date evaluating safety and efficacy of SBRT in an elderly population. In our series, elderly patients undergoing SBRT appear to have achieved similar outcomes and toxicity compared to younger patients.

Download ppt "S L I D E 0 Elderly Patients Undergoing SBRT for Inoperable Early Stage NSCLC Achieve Similar Outcomes to Younger Patients Brandon R. Mancini, Henry S."

Similar presentations

I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days 1 2 22 36 50 64 92 E V A L U A.

I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days E V A L U A.
Treatment in Advanced Non-Small Cell Lung Cancer.

Treatment in Advanced Non-Small Cell Lung Cancer.
Facon T et al. Proc ASH 2013;Abstract 2.

Facon T et al. Proc ASH 2013;Abstract 2.
Rib fracture after 177 patients with Hiroshi Onishi, Hiroshi Onishi, Rihito Tominaga, Marino, Takafumi Komiyama, Kengo University of Yamanashi,

Rib fracture after 177 patients with Hiroshi Onishi, Hiroshi Onishi, Rihito Tominaga, Marino, Takafumi Komiyama, Kengo University of Yamanashi,
Casulo C et al. Proc ASH 2013;Abstract 510.

Casulo C et al. Proc ASH 2013;Abstract 510.
21th WCC, Shenzhen, China, Aug 19, 2010 Guo-Liang Jiang, MD, FACR Min Fan, MD, Jiayan Chen, MD Fudan University Shanghai Cancer Center Combination of radiation.

21th WCC, Shenzhen, China, Aug 19, 2010 Guo-Liang Jiang, MD, FACR Min Fan, MD, Jiayan Chen, MD Fudan University Shanghai Cancer Center Combination of radiation.
Pulmonary Metastasis From Osteosarcoma Multi-factorial analysis of survival at first lung involvement Ali Aljubran, Martin Blackstein for the University.

Pulmonary Metastasis From Osteosarcoma Multi-factorial analysis of survival at first lung involvement Ali Aljubran, Martin Blackstein for the University.
Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer. First report for inoperable population of a phase II trial by Japan Clinical.

Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer. First report for inoperable population of a phase II trial by Japan Clinical.
Evaluating a Nomogram for the Development of Radiation Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer Treated with 3D and Intensity Modulated.

Evaluating a Nomogram for the Development of Radiation Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer Treated with 3D and Intensity Modulated.
Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.
Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.

Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.

1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Www.siteman.wustl.edu A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.
S L I D E 0 Invasive Mediastinal Staging Does Not Improve Outcomes Over PET Alone in Early-Stage NSCLC Treated with SBRT Christopher D. Corso MD PhD, Shane.

S L I D E 0 Invasive Mediastinal Staging Does Not Improve Outcomes Over PET Alone in Early-Stage NSCLC Treated with SBRT Christopher D. Corso MD PhD, Shane.
ICNCT-16, , Helsinki, Finland

ICNCT-16, , Helsinki, Finland
Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,

Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,
Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use Of Angiotensin- Converting Enzyme Inhibitors In Patients Receiving Lung Stereotactic.

Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use Of Angiotensin- Converting Enzyme Inhibitors In Patients Receiving Lung Stereotactic.
A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma.

A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.

Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.

Similar presentations

Ads by Google